Combination therapy for the treatment of pulmonary mold infections

References

• Chamilos G, Marom EM, Lewis RE, et al. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis. 2005;41(1):60–66.
   PubMed Web of Science ®Google Scholar
• Riley TT, Muzny CA, Swiatlo E, et al. Breaking the mold: a review of mucormycosis and current pharmacological treatment options. Ann Pharmacother. 2016;50(9):747–757.
   PubMed Web of Science ®Google Scholar
• Arendrup MC, Meletiadis J, Mouton JW, et al. EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents. Clin Microbiol Infect. 2016;22(6):571.e1–571.e4.
   Web of Science ®Google Scholar
• Denning DW, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J. 2016;47(1):45–68.
   PubMed Web of Science ®Google Scholar
• Badior M, Trigo F, Eloy C, et al. Mucor infection: difficult diagnosis. Clin Drug Investig. 2013;33(Suppl 1):S19–S21.
   PubMed Web of Science ®Google Scholar
• Dignani MC, Anaissie E. Human fusariosis. Clin Microbiol Infect. 2004;10(Suppl 1):67–75.
   PubMed Web of Science ®Google Scholar
• Wong EH, Revankar SG. Dematiaceous molds. Infect Dis Clin North Am. 2016;30(1):165–178.
   PubMed Web of Science ®Google Scholar
• Mello TP, Aor AC, Gonçalves DS, et al. Assessment of biofilm formation by Scedosporium apiospermum, S. aurantiacum, S. minutisporum and Lomentospora prolificans. Biofouling. 2016;32(7):737–749.
   PubMed Web of Science ®Google Scholar
• Arendrup MC, Jensen RH, Cuenca-Estrella M. In Vitro Activity of ASP2397 against Aspergillus Isolates with or without acquired azole resistance mechanisms. Antimicrob Agents Chemother. 2016;60(1):532–536.
   PubMed Web of Science ®Google Scholar
• Enoch DA, Yang H, Aliyu SH, et al. The changing epidemiology of invasive fungal infections. Methods Mol Biol. 2017;1508:17–65.
   PubMedGoogle Scholar
• Mariette C, Tavernier E, Hocquet D, et al. Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: a GRAALL-2005 study. Leuk Lymphoma. 2016;58:1–8.
   PubMed Web of Science ®Google Scholar
• Emminger W, Graninger W, Emminger-Schmidmeier W, et al. Tolerance of high doses of amphotericin B by infusion of a liposomal formulation in children with cancer. Ann Hematol. 1994;68(1):27–31.
   PubMed Web of Science ®Google Scholar
• Prigitano A, Esposto MC, Biffi A, et al. Triazole resistance in Aspergillus fumigatus isolates from patients with cystic fibrosis in Italy. J Cyst Fibros. 2016;16:64-69.
   PubMed Web of Science ®Google Scholar
• Perlin DS. Echinocandin Resistance in Candida. Clin Infect Dis. 2015;61(Suppl 6):S612–S617.
   PubMed Web of Science ®Google Scholar
• Safdar A, Rodriguez G, Zuniga J, et al. High-dose caspofungin as a component of combination antifungal therapy in 91 patients with neoplastic diseases and hematopoietic stem cell transplantation: a critical review of short-term and long-term adverse events. J Pharm Pract. 2015;28(2):175–182.
   PubMedGoogle Scholar
• Safdar A, Rodriguez G, Rolston KV, et al. High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;39(3):157–164.
   PubMed Web of Science ®Google Scholar
• Anderson TM, Clay MC, Cioffi AG, et al. Amphotericin forms an extramembranous and fungicidal sterol sponge. Nat Chem Biol. 2014;10(5):400–406.
   PubMed Web of Science ®Google Scholar
• Verweij PE, Ananda-Rajah M, Andes D, et al. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resist Updat. 2015;21-22:30–40.
   PubMed Web of Science ®Google Scholar
• Dolton MJ, Perera V, Pont LG, et al. Terbinafine in combination with other antifungal agents for treatment of resistant or refractory mycoses: investigating optimal dosing regimens using a physiologically based pharmacokinetic model. Antimicrob Agents Chemother. 2014;58(1):48–54.
   PubMed Web of Science ®Google Scholar
• Fournier A, Pantet O, Guerid S, et al. Effective treatment of invasive Aspergillus fumigatus infection using combinations of topical and systemic antifungals in a severely burned patient. J Burn Care Res. 2015;36(2):e85–e89.
   PubMed Web of Science ®Google Scholar
• Foucquier J, Guedj M. Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect. 2015;3(3):e00149.
   PubMed Web of Science ®Google Scholar
• Meletiadis J, Pournaras S, Roilides E, et al. Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus. Antimicrob Agents Chemother. 2010;54(2):602–609.
   PubMed Web of Science ®Google Scholar
• Nieuwenhuis S, Forstmann BU, Wagenmakers EJ. Erroneous analyses of interactions in neuroscience: a problem of significance. Nat Neurosci. 2011;14(9):1105–1107.
   PubMed Web of Science ®Google Scholar
• Lehár J, Zimmermann GR, Krueger AS, et al. Chemical combination effects predict connectivity in biological systems. Mol Syst Biol. 2007;3:80.
   PubMed Web of Science ®Google Scholar
• Slinker BK. The statistics of synergism. J Mol Cell Cardiol. 1998;30(4):723–731.
   PubMed Web of Science ®Google Scholar
• Geary N. Understanding synergy. Am J Physiol Endocrinol Metab. 2013;304(3):E237–E253.
   PubMed Web of Science ®Google Scholar
• Baeder DY, Yu G, Hozé N, et al. Antimicrobial combinations: bliss independence and Loewe additivity derived from mechanistic multi-hit models. Philos Trans R Soc Lond B Biol Sci. 2016;371:1695.
   Web of Science ®Google Scholar
• Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database. Clin Infect Dis. 2010;50(8):1091–1100.
   PubMed Web of Science ®Google Scholar
• Rickerts V, Just-Nübling G, Konrad F, et al. Diagnosis of invasive aspergillosis and mucormycosis in immunocompromised patients by seminested PCR assay of tissue samples. Eur J Clin Microbiol Infect Dis. 2006;25(1):8–13.
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Roedlich MN. Earlier diagnosis of angioinvasive pulmonary mold disease: is computed tomography pulmonary angiography a new step? Clin Infect Dis. 2012;54(5):617–620.
   PubMed Web of Science ®Google Scholar
• Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634–653.
   PubMed Web of Science ®Google Scholar
• Pyrgos V, Shoham S, Walsh TJ. Pulmonary zygomycosis. Semin Respir Crit Care Med. 2008;29(2):111–120.
   PubMed Web of Science ®Google Scholar
• Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med. 2006;173(7):707–717.
   PubMed Web of Science ®Google Scholar
• Denning DW, Bromley MJ. Infectious disease. How to bolster the antifungal pipeline. Science. 2015;347(6229):1414–1416.
   PubMed Web of Science ®Google Scholar
• Trullas JC, Cervera C, Benito N, et al. Invasive pulmonary aspergillosis in solid organ and bone marrow transplant recipients. Transplant Proc. 2005;37(9):4091–4093.
   PubMed Web of Science ®Google Scholar
• Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer. 2006;107(12):2888–2897.
   PubMed Web of Science ®Google Scholar
• George D, Kordick D, Miniter P, et al. Combination therapy in experimental invasive aspergillosis. J Infect Dis. 1993;168(3):692–698.
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis. 2003;187(12):1834–1843.
   PubMed Web of Science ®Google Scholar
• Lewis RE, Kontoyiannis DP. Rationale for combination antifungal therapy. Pharmacotherapy. 2001;21(8 Pt 2):149S–164S.
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Hope WW, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. Antimicrob Agents Chemother. 2009;53(6):2382–2391.
   PubMed Web of Science ®Google Scholar
• Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004;39(6):797–802.
   PubMed Web of Science ®Google Scholar
• Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med. 2015;162(2):81–89.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer. 2003;98(2):292–299.
   PubMed Web of Science ®Google Scholar
• Caillot D, Thiébaut A, Herbrecht R, et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer. 2007;110(12):2740–2746.
   PubMed Web of Science ®Google Scholar
• Meletiadis J, Petraitis V, Petraitiene R, et al. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J Infect Dis. 2006;194(7):1008–1018.
   PubMed Web of Science ®Google Scholar
• Clemons KV, Parmar R, Martinez M, et al. Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis. J Antimicrob Chemother. 2006;58(2):466–469.
   PubMed Web of Science ®Google Scholar
• Polak A. Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice. Chemotherapy. 1987;33(5):381–395.
   PubMed Web of Science ®Google Scholar
• Hughes CE, Harris C, Moody JA, et al. In vitro activities of amphotericin B in combination with four antifungal agents and rifampin against Aspergillus spp. Antimicrob Agents Chemother. 1984;25(5):560–562.
   PubMed Web of Science ®Google Scholar
• Johnson MD, MacDougall C, Ostrosky-Zeichner L, et al. Combination antifungal therapy. Antimicrob Agents Chemother. 2004;48(3):693–715.
   PubMed Web of Science ®Google Scholar
• Siopi M, Siafakas N, Vourli S, et al. Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model. Antimicrob Agents Chemother. 2015;59(7):3973–3983.
   PubMed Web of Science ®Google Scholar
• Taj-Aldeen SJ, Gamaletsou MN, Rammaert B, et al. Bone and joint infections caused by mucormycetes: a challenging osteoarticular mycosis of the twenty-first century. Med Mycol. 2017.
   Google Scholar
• Gomes MZ, Lewis RE, Kontoyiannis DP. Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species. Clin Microbiol Rev. 2011;24(2):411–445.
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Spellberg B, Walsh TJ, et al. Pathogenesis of mucormycosis. Clin Infect Dis. 2012;54(Suppl 1):S16–S22.
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Spellberg B, Edwards J. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis. 2008;21(6):620–625.
   PubMed Web of Science ®Google Scholar
• Spellberg B, Walsh TJ, Kontoyiannis DP, et al. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis. 2009;48(12):1743–1751.
   PubMed Web of Science ®Google Scholar
• Spellberg B, Ibrahim A, Roilides E, et al. Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis. 2012;54(Suppl 1):S73–S78.
   PubMed Web of Science ®Google Scholar
• Wang XM, Guo LC, Xue SL, et al. Pulmonary mucormycosis: a case report and review of the literature. Oncol Lett. 2016;11(5):3049–3053.
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Bowman JC, Avanessian V, et al. Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother. 2005;49(2):721–727.
   PubMed Web of Science ®Google Scholar
• Spellberg B, Fu Y, Edwards JE, et al. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother. 2005;49(2):830–832.
   PubMed Web of Science ®Google Scholar
• Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008;47(3):364–371.
   PubMed Web of Science ®Google Scholar
• Kyvernitakis A, Torres HA, Jiang Y, et al. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. Clin Microbiol Infect. 2016;22(9):811.e1–811.e8.
   PubMed Web of Science ®Google Scholar
• Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2016;102:433-444.
   PubMedGoogle Scholar
• Gebremariam T, Wiederhold NP, Alqarihi A, et al. Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis. J Antimicrob Chemother. 2016;72:462-466.
   PubMed Web of Science ®Google Scholar
• Chitasombat MN, Kontoyiannis DP. Treatment of mucormycosis in transplant patients: role of surgery and of old and new antifungal agents. Curr Opin Infect Dis. 2016;29(4):340–345.
   PubMed Web of Science ®Google Scholar
• Ballester F, Pastor FJ, Guarro J. In vitro activities of combinations of amphotericin B, posaconazole and four other agents against Rhizopus. J Antimicrob Chemother. 2008;61(3):755–757.
   PubMed Web of Science ®Google Scholar
• Rodríguez MM, Serena C, Mariné M, et al. Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. Antimicrob Agents Chemother. 2008;52(10):3786–3788.
   PubMed Web of Science ®Google Scholar
• Lebeau O, Van Delden C, Garbino J, et al. Disseminated Rhizopus microsporus infection cured by salvage allogeneic hematopoietic stem cell transplantation, antifungal combination therapy, and surgical resection. Transpl Infect Dis. 2010;12(3):269–272.
   PubMed Web of Science ®Google Scholar
• Farmakiotis D, Kontoyiannis DP. Mucormycoses. Infect Dis Clin North Am. 2016;30(1):143–163.
   PubMed Web of Science ®Google Scholar
• Pagano L, Cornely OA, Busca A, et al. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica. 2013;98(10):e127–e130.
   PubMed Web of Science ®Google Scholar
• van Diepeningen AD, Brankovics B, Iltes J, et al. Diagnosis of fusarium infections: approaches to identification by the Clinical Mycology Laboratory. Curr Fungal Infect Rep. 2015;9(3):135–143.
   PubMedGoogle Scholar
• McCarthy M, Rosengart A, Schuetz AN, et al. Mold infections of the central nervous system. N Engl J Med. 2014;371(2):150–160.
   PubMed Web of Science ®Google Scholar
• Montejo M, Muñiz ML, Zárraga S, et al. Case reports. Infection due to Scedosporium apiospermum in renal transplant recipients: a report of two cases and literature review of central nervous system and cutaneous infections by Pseudallescheria boydii/Sc. apiospermum. Mycoses. 2002;45(9–10):418–427.
   PubMed Web of Science ®Google Scholar
• Cortez KJ, Roilides E, Quiroz-Telles F, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev. 2008;21(1):157–197.
   PubMed Web of Science ®Google Scholar
• Lortholary O, Obenga G, Biswas P, et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother. 2010;54(10):4446–4450.
   PubMed Web of Science ®Google Scholar
• Nucci M, Marr KA, Vehreschild MJ, et al. Improvement in the outcome of invasive fusariosis in the last decade. Clin Microbiol Infect. 2014;20(6):580–585.
   PubMed Web of Science ®Google Scholar
• Steinberg GK, Britt RH, Enzmann DR, et al. Fusarium brain abscess. Case report. J Neurosurg. 1983;58(4):598–601.
   PubMed Web of Science ®Google Scholar
• Tupaki-Sreepurna A, Al-Hatmi AM, Kindo AJ, et al. Multidrug-resistant Fusarium in keratitis: a clinico-mycological study of keratitis infections in Chennai, India. Mycoses. 2016;60:230-233.
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev. 2007;20(4):695–704.
   PubMed Web of Science ®Google Scholar
• Martino P, Gastaldi R, Raccah R, et al. Clinical patterns of Fusarium infections in immunocompromised patients. J Infect. 1994;28(Suppl 1):7–15.
   PubMedGoogle Scholar
• Rabodonirina M, Piens MA, Monier MF, et al. Fusarium infections in immunocompromised patients: case reports and literature review. Eur J Clin Microbiol Infect Dis. 1994;13(2):152–161.
   PubMed Web of Science ®Google Scholar
• Anaissie E, Paetznick V, Proffitt R, et al. Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur J Clin Microbiol Infect Dis. 1991;10(8):665–668.
   PubMed Web of Science ®Google Scholar
• Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years’ experience at a cancer center and implications for management. Blood. 1997;90(3):999–1008.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Hiemenz JW, Anaissie E. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Infect Dis Clin North Am. 1996;10(2):365–400.
   PubMed Web of Science ®Google Scholar
• Nucci F, Nouér SA, Capone D, et al. Fusariosis. Semin Respir Crit Care Med. 2015;36(5):706–714.
   PubMed Web of Science ®Google Scholar
• Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36(9):1122–1131.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Schmitz K, Aisenbrey S. The first echinocandin: caspofungin. Mycoses. 2002;45(Suppl 3):56–60.
   PubMed Web of Science ®Google Scholar
• Córdoba S, Rodero L, Vivot W, et al. In vitro interactions of antifungal agents against clinical isolates of Fusarium spp. Int J Antimicrob Agents. 2008;31(2):171–174.
   PubMed Web of Science ®Google Scholar
• Blyth CC, Middleton PG, Harun A, et al. Clinical associations and prevalence of Scedosporium spp. in Australian cystic fibrosis patients: identification of novel risk factors? Med Mycol. 2010;48(Suppl 1):S37–S44.
   PubMed Web of Science ®Google Scholar
• Han Z, Kautto L, Nevalainen H. Secretion of proteases by an opportunistic fungal pathogen scedosporium aurantiacum. PLoS One. 2017;12(1):e0169403.
   PubMed Web of Science ®Google Scholar
• Gruber M, Moser I, Nagl M, et al. Bactericidal and fungicidal activity of N-chlorotaurine is enhanced in cystic fibrosis sputum medium. Antimicrob Agents Chemother. 2017.
   PubMedGoogle Scholar
• Koga T, Kitajima T, Tanaka R, et al. Chronic pulmonary scedosporiosis simulating aspergillosis. Respirology. 2005;10(5):682–684.
   PubMed Web of Science ®Google Scholar
• Rahman FU, Irfan M, Fasih N, et al. Pulmonary scedosporiosis mimicking aspergilloma in an immunocompetent host: a case report and review of the literature. Infection. 2016;44(1):127–132.
   PubMed Web of Science ®Google Scholar
• Kim SH, Ha YE, Youn JC, et al. Fatal scedosporiosis in multiple solid organ allografts transmitted from a nearly-drowned donor. Am J Transplant. 2015;15(3):833–840.
   PubMed Web of Science ®Google Scholar
• Taylor A, Talbot J, Bennett P, et al. Disseminated Scedosporium prolificans infection in a Labrador retriever with immune mediated haemolytic anaemia. Med Mycol Case Rep. 2014;6:66–69.
   PubMedGoogle Scholar
• Hartmann C, Müller C, Weißbrodt H, et al. Successful prevention of scedosporiosis after lung transplantation in a cystic fibrosis patient by combined local and systemic triazole therapy. Med Mycol Case Rep. 2013;2:116–118.
   PubMedGoogle Scholar
• Holmes NE, Trevillyan JM, Kidd SE, et al. Locally extensive angio-invasive Scedosporium prolificans infection following resection for squamous cell lung carcinoma. Med Mycol Case Rep. 2013;2:98–102.
   PubMedGoogle Scholar
• Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother. 2006;50(3):917–921.
   PubMed Web of Science ®Google Scholar
• Johnson EM, Szekely A, Warnock DW. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother. 1998;42(6):741–745.
   PubMed Web of Science ®Google Scholar
• Miyazaki M, Horii T, Hata K, et al. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrob Agents Chemother. 2011;55(10):4652–4658.
   PubMed Web of Science ®Google Scholar
• Guinea J, Peláez T, Recio S, et al. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother. 2008;52(4):1396–1400.
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Johnson E, Hockey H, et al. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies. J Antimicrob Chemother. 2008;61(3):616–620.
   PubMed Web of Science ®Google Scholar
• Halliday CL, Chen SC, Kidd SE, et al. Antifungal susceptibilities of non-Aspergillus filamentous fungi causing invasive infection in Australia: support for current antifungal guideline recommendations. Int J Antimicrob Agents. 2016;48(4):453–458.
   PubMed Web of Science ®Google Scholar
• Lackner M, Hagen F, Meis JF, et al. Susceptibility and diversity in the therapy-refractory genus scedosporium. Antimicrob Agents Chemother. 2014;58(10):5877–5885.
   PubMed Web of Science ®Google Scholar
• Heyn K, Tredup A, Salvenmoser S, et al. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob Agents Chemother. 2005;49(12):5157–5159.
   PubMed Web of Science ®Google Scholar
• Safdar A. Fungal cytoskeleton dysfunction or immune activation triggered by beta-glucan synthase inhibitors: potential mechanisms for the prolonged antifungal activity of echinocandins. Cancer. 2009;115(13):2812–2815.
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Schell WA, Miller JL, et al. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. J Clin Microbiol. 2003;41(8):3981–3985.
   PubMed Web of Science ®Google Scholar
• Troke P, Aguirrebengoa K, Arteaga C, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother. 2008;52(5):1743–1750.
   PubMed Web of Science ®Google Scholar
• Perfect JR. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis. 2005;40(Suppl 6):S401–S408.
   PubMed Web of Science ®Google Scholar
• Capilla J, Mayayo E, Serena C, et al. A novel murine model of cerebral scedosporiosis: lack of efficacy of amphotericin B. J Antimicrob Chemother. 2004;54(6):1092–1095.
   PubMed Web of Science ®Google Scholar
• Naggie S, Perfect JR. Molds: hyalohyphomycosis, phaeohyphomycosis, and zygomycosis. Clin Chest Med. 2009;30(2):337–353, vii–viii.
   PubMed Web of Science ®Google Scholar
• Al-Tawfiq JA, Boukhamseen A. Cerebral phaeohyphomycosis due to Rhinocladiella mackenziei (formerly Ramichloridium mackenziei): case presentation and literature review. J Infect Public Health. 2011;4(2):96–102.
   PubMedGoogle Scholar
• Ben-Ami R, Lewis RE, Raad II, et al. Phaeohyphomycosis in a tertiary care cancer center. Clin Infect Dis. 2009;48(8):1033–1041.
   PubMed Web of Science ®Google Scholar
• Revankar SG, Sutton DA, Rinaldi MG. Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clin Infect Dis. 2004;38(2):206–216.
   PubMed Web of Science ®Google Scholar
• O’Shea PM, Griffin TP, Fitzgibbon M. Hypertension: the role of biochemistry in the diagnosis and management. Clin Chim Acta. 2016;18:31-37.
   Google Scholar
• Weiss A, Nowak-Sliwinska P. Current trends in multidrug optimization. J Lab Autom. 2016;10:2472630316682338.
   Google Scholar
• Frigati L, Wynberg E, Maritz J, et al. Antiretroviral treatment initiated in the first month of life. Pediatr Infect Dis J. 2016;36:110-120.
   Google Scholar
• Albertson TE, Bullick SW, Schivo M, et al. Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: design, development and place in therapy. Drug Des Devel Ther. 2016;10:4047–4060.
   PubMed Web of Science ®Google Scholar
• Steinbach WJ. Combination antifungal therapy for invasive aspergillosis: utilizing new targeting strategies. Curr Drug Targets Infect Disord. 2005;5(3):203–210.
   PubMedGoogle Scholar
• Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1–e60.
   PubMed Web of Science ®Google Scholar
• Mukherjee PK, Sheehan DJ, Hitchcock CA, et al. Combination treatment of invasive fungal infections. Clin Microbiol Rev. 2005;18(1):163–194.
   PubMed Web of Science ®Google Scholar
• Spitzer M, Robbins N, Wright GD. Combinatorial strategies for combating invasive fungal infections. Virulence. 2017;8(2):169–185.
   PubMed Web of Science ®Google Scholar
• Candoni A, Aversa F, Busca A, et al. Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data. J Chemother. 2015;27(1):1–12.
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Olaechea P, Alvarez-Lerma F, et al. Epidemiology, diagnosis and treatment of fungal respiratory infections in the critically ill patient. Rev Esp Quimioter. 2013;26(2):173–188.
   PubMed Web of Science ®Google Scholar
• Martin-Vicente A, Capilla J, Guarro J. Synergistic effect of anidulafungin combined with posaconazole in experimental aspergillosis. Med Mycol. 2016.
   PubMedGoogle Scholar
• Yao L, Wan Z, Li R, et al. In vitro triple combination of antifungal drugs against clinical scopulariopsis and microascus species. Antimicrob Agents Chemother. 2015;59(8):5040–5043.
   PubMed Web of Science ®Google Scholar
• Wilson DT, Dimondi VP, Johnson SW, et al. Role of isavuconazole in the treatment of invasive fungal infections. Ther Clin Risk Manag. 2016;12:1197–1206.
   PubMed Web of Science ®Google Scholar
• Kovanda LL, Maher R, Hope WW. Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis. Expert Rev Clin Pharmacol. 2016;9(7):887–897.
   PubMed Web of Science ®Google Scholar
• Townsend R, Dietz A, Hale C, et al. Pharmacokinetic evaluation of CYP3A4-mediated drug-drug interactions of isavuconazole with rifampin, ketoconazole, midazolam, and ethinyl estradiol/norethindrone in healthy adults. Clin Pharmacol Drug Dev. 2016;6:44-53.
   PubMed Web of Science ®Google Scholar
• Walker RC, Zeuli JD, Temesgen Z. Isavuconazonium sulfate for the treatment of fungal infection. Drugs Today (Barc). 2016;52(1):7–16.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Böhme A, Schmitt-Hoffmann A, et al. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Antimicrob Agents Chemother. 2015;59(4):2078–2085.
   PubMed Web of Science ®Google Scholar
• Katragkou A, McCarthy M, Meletiadis J, et al. In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds. Antimicrob Agents Chemother. 2014;58(11):6934–6937.
   PubMed Web of Science ®Google Scholar
• Osherov N, Kontoyiannis DP. The anti-Aspergillus drug pipeline: is the glass half full or empty? Med Mycol. 2016;55:118-124.
   PubMed Web of Science ®Google Scholar
• Shibata T, Takahashi T, Yamada E, et al. T-2307 causes collapse of mitochondrial membrane potential in yeast. Antimicrob Agents Chemother. 2012;56(11):5892–5897.
   PubMed Web of Science ®Google Scholar
• Watanabe NA, Miyazaki M, Horii T, et al. Hata K. E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis. Antimicrob Agents Chemother. 2012;56(2):960–971.
   PubMed Web of Science ®Google Scholar
• Compain F, Botterel F, Sitterlé E, et al. In vitro activity of miltefosine in combination with voriconazole or amphotericin B against clinical isolates of Scedosporium spp. J Med Microbiol. 2015;64(Pt 3):309–311.
   PubMed Web of Science ®Google Scholar
• Trubiano JA, Paratz E, Wolf M, et al. Disseminated Scedosporium prolificans infection in an ‘extensive metaboliser’: navigating the minefield of drug interactions and pharmacogenomics. Mycoses. 2014;57(9):572–576.
   PubMed Web of Science ®Google Scholar
• Kesson AM, Bellemore MC, O’Mara TJ, et al. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with a novel agent, hexadecylphospocholine (miltefosine), in combination with terbinafine and voriconazole: a case report. Clin Infect Dis. 2009;48(9):1257–1261.
   PubMed Web of Science ®Google Scholar
• Martin-Vicente A, Guarro J, Capilla J. Does a triple combination have better activity than double combinations against multiresistant fungi? Experimental in vitro evaluation. Int J Antimicrob Agents. 2017;49:422-426.
   PubMed Web of Science ®Google Scholar
• Panackal AA. Combination antifungal therapy for invasive aspergillosis revisited. Med Mycol Open Access. 2016;2:2.
   PubMedGoogle Scholar